Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine subcutaneous - Britannia Pharmaceuticals

Drug Profile

Apomorphine subcutaneous - Britannia Pharmaceuticals

Alternative Names: APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; MOVAPO®; SPN-830

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Kyowa Kirin; STADA Arzneimittel; Supernus Pharmaceuticals; US WorldMeds
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 02 Nov 2023 FDA assigns PDUFA action date of 5/04/2024 for apomorphine subcutaneous for Parkinson’s disease (Infusion pump)
  • 02 Nov 2023 US FDA accepts NDA for apomorphine subcutaneous for Parkinson’s disease (Infusion pump) for review
  • 09 May 2023 Supernus Pharmaceuticals plans to resubmit the new drug application (NDA) for Apomorphine subcutaneous in Parkinson’s disease (Infusion pump) in the fourth quarter of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top